Japan Investment Corp (JIC), the state-backed fund overseen by the Japanese trade ministry, is considering selling JSR Corp, the maker of photoresists and other chipmaking materials it took private in a $6 billion deal two years ago, and the timing – which NewsTrackerToday clocked immediately as the operative factor in the sale consideration – is not coincidental. Massive investments in AI have lifted valuations across the semiconductor supply chain, and JIC is now looking to capitalize on those buoyant conditions rather than continue holding the asset through its originally stated consolidation mission. Sources familiar with the matter said Fujifilm and Mitsubishi Chemical have expressed interest in acquiring the company. JIC, JSR, Fujifilm, and Mitsubishi Chemical all declined to comment.
JSR was established in 1957 and is one of the world’s leading manufacturers of photoresists, the light-sensitive chemical compounds used to transfer circuit patterns onto semiconductor wafers. The material sits at a critical step in the chip fabrication process: without photoresists, there is no patterning, without patterning there are no chips. JSR competes in this market with Japan’s Tokyo Ohka Kogyo, Shin-Etsu Chemical, and JSR’s global rival Dow. Fujifilm also manufactures photoresists, which makes it a logical strategic acquirer with potential for cost synergies. Mitsubishi Chemical makes precursor chemicals that go into photoresist formulations, which positions it differently – less a direct competitor and more a company looking to integrate further up the supply chain.
Isabella Moretti, who covers corporate strategy and M&A, examines what the exit decision reveals about JIC’s mandate: “JIC took JSR private to consolidate Japan’s fragmented chipmaking materials sector. Two years in, JSR’s new CEO said last year that the company was focused on restoring business performance and was not ready to make acquisitions. So JIC’s consolidation thesis stalled on the operational side. Now the AI valuation boom has created an exit window that didn’t exist when the original deal closed. The question is whether Fujifilm or Mitsubishi Chemical can execute the consolidation play JIC originally envisioned – or whether they’re just buying the asset at a higher price and parking it.” The irony of JIC’s position – a state fund selling a national champion asset at peak AI valuations rather than building the strategic platform it intended – is what the specific context NewsTrackerToday surfaces: JSR logged a net profit of 60.7 billion yen on revenue of 400.7 billion yen in the year ended March, returning to profitability after its life sciences business had dragged results the prior year.
Liam Anderson reads the market signal: “Tokyo Ohka Kogyo shares have tripled in the past year, giving it a 1.4 trillion yen valuation. JSR is bigger and more complex but broadly in the same sector. If JIC bought it at around 6 billion dollars two years ago and AI has inflated chip materials valuations by 3x, the arithmetic on a sale is compelling. The strategic logic of holding is weaker than the financial logic of selling into the current window.” The AI valuation uplift across Japan’s semiconductor materials sector is the structural factor that makes JSR’s sale consideration rational regardless of whether the consolidation mission was accomplished. Japan has numerous companies making niche but essential chipmaking materials and equipment, many of which have seen their valuations surge. JSR is among the most significant.
The geopolitical dimension matters here too. Photoresists are subject to export controls by Japan, which in 2023 imposed restrictions on 23 categories of semiconductor manufacturing equipment and materials to align with U.S. and Dutch restrictions on advanced chipmaking technology. A transaction involving JSR requires approval from Japan’s Ministry of Economy, Trade and Industry, and any foreign buyer – which neither Fujifilm nor Mitsubishi Chemical is – would face an additional layer of national security scrutiny. The interested parties are both Japanese, which simplifies the approval path considerably. Still, a METI review of the national strategic implications of concentrating photoresist production within a smaller number of Japanese corporate hands is what News Tracker Today put in context as the regulatory variable that determines whether either deal can close on the timeline that JIC’s exit window appears to require.
Three things to watch as this process develops: whether JIC runs a formal sale process or negotiates bilaterally with one of the named interested parties, since the two approaches produce very different price dynamics; whether a non-Japanese party enters the conversation despite the likely METI friction, given that TSMC, Samsung, or an advanced materials company from the U.S. or Europe might value JSR at a meaningful premium over domestic buyers; and whether JSR’s management team, which has spent two years focused on operational recovery rather than deal-making, is aligned with the sale timeline JIC appears to be considering. The answer to that last question is the one that NewsTrackerToday cross-checked against the publicly available record on JSR’s new CEO: his stated focus in 2025 was performance restoration, not exit readiness.
